

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 August 2006 (31.08.2006)

PCT

(10) International Publication Number
WO 2006/090167 A3

(51) International Patent Classification:

C07D 251/70 (2006.01) *A61K 31/506* (2006.01)
C07D 403/04 (2006.01) *A61K 31/517* (2006.01)
A61K 31/53 (2006.01)

(21) International Application Number:

PCT/GB2006/000668

(22) International Filing Date:

24 February 2006 (24.02.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0503962.3 25 February 2005 (25.02.2005) GB
60/656,193 25 February 2005 (25.02.2005) US

(71) Applicant (for all designated States except US): **KUDOS PHARMACEUTICALS LIMITED** [GB/GB];
327 Cambridge Science Park, Milton Road, Cambridge
Cambridgeshire CB4 0WG (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HUMMERSONE, Marc Geoffrey** [GB/GB]; Kudos Pharmaceuticals Limited, 327 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0WG (GB). **GOMEZ, Sylvie** [FR/GB]; Kudos Pharmaceuticals Limited, 327 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire

CB4 0WG (GB). **MENEAR, Keith Allan** [GB/GB]; Kudos Pharmaceuticals Limited, 327 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0WG (GB). **COCKCROFT, Xiao-ling Fan** [GB/GB]; Kudos Pharmaceuticals Limited, 327 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0WG (GB). **SMITH, Graeme Cameron Murray** [GB/GB]; Kudos Pharmaceuticals Limited, 327 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0WG (GB).


(74) Agents: **WATSON, Robert** et al.; Mewburn Ellis LLP, York House, 23 Kingsway, London Greater London WC2B 6HP (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,

[Continued on next page]

(54) Title: HYDRAZINOMETHYL, HYDR ZONOMETHYL AND 5-MEMBERED HETEROCYCLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS



(57) Abstract: Compounds of formula (I): A-B-C and isomers, salts, solvates, chemically protected forms, and prodrugs thereof wherein: B is selected from the group consisting of formula (i) where R^N is H or Me; or B is a divalent C_5 heterocyclic residue containing one or two ring heteroatoms; A is formula (ii) R^{A3} and R^{A5} are independently selected from halo, OR^O and R^{AC} , where R^O is H or Me, and R^{AC} is H or C_{1-4} alkyl; X^A is selected from N and CR^{A4} , where R^{A4} is selected from H, OR^O , CH_2OH , CO_2H , $NHSO_2Me$ and $NHCOMe$; R^{A2} and R^{A6} are independently selected from H, halo and OR^O ; or R^{A3} and R^{A4} together with the carbon atoms to which they are attached, or $RA2$ and R^{A3} together with the carbon atoms to which they are attached, may form a C_{5-6} heterocyclic or heteroaromatic ring, containing at least one nitrogen ring atom; where if X is not N, 1, 2, or 3 of R^{A2} to R^{A6} are not H; C is formula (iii) where X is selected from N and CH, Y is selected from N and CH, and Z is selected from N and CR^{C6} ; R^{C3} is selected from H, halo and an optionally substituted N-containing C_{5-7} heterocyclic group; R_{C5} is a group selected from formula (iv) which group may be selected by one or two C_{1-4} alkyl groups or a carboxy group; R^{C6} is H; or, when X and Y are N, R^{C5} and R^{C6} (when Z is CR^{C6}) together with the carbon atoms to which they are attached may form a fused C_6 aromatic ring selected from the group consisting of formula (v).

WO 2006/090167 A3



FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments*

Declaration under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

(88) Date of publication of the international search report:

10 May 2007

Published:

— *with international search report*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*